VIVUS, Inc.(VVUS): For the most recent quarter end, VIVUS, Inc. reported Annual Earnings of $-0.09. Based on the filings, last years Annual Earnings was, $-0.62. For the most recent quarter end, VVUS reported a surprise Earnings per Share of 64% . The consensus estimate for current quarter is $-0.09 and for the current fiscal year, the estimate is $-0.41. For the Next fiscal year, the estimate is $-0.5 based on the consensus.
VIVUS, Inc. has received $-0.09 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 1 Financial Advisor in the Stock Trading Firms. The EPS growth rate is projected at 25%. VIVUS, Inc. reported better than expected with a surprise EPS of 64% or $0.16 during its most recent quarterly earnings. The Actual EPS was $-0.09 compared to the Estimated EPS of $-0.25.
VIVUS Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.10. Analyst had a consensus of $-0.19. The company had revenue of $13.40 million for the quarter, compared to analysts expectations of $13.04 million. The companys revenue was down -46.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.15 EPS.
Company has reported several Insider transactions to the SEC, on Jan 31, 2017, Santosh T Varghese (Chief Medical Officer) sold 429 shares at 1.11 per share price.On Apr 20, 2016, John L Slebir (SVP, Business Development & GC) sold 9,933 shares at 2.20 per share price.On Apr 20, 2016, Guy P Marsh (VP, US Operations & GM) sold 633 shares at 3.04 per share price.
VIVUS, Inc. (NASDAQ:VVUS) rose 0.91% or 0.01 points on Wednesday and made its way into the gainers of the day. After trading began at $1.1 the stock was seen hitting $1.12 as a peak level and $1.08 as the lowest level. The stock ended up at $1.11. The daily volume was measured at 706,000 shares. The 52-week high of the share price is $1.85 and the 52-week low is $0.93. The company has a market cap of $116 million.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The companys lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.